4-Carvomentenol, a monoterpene of essential oils, reduces airway inflammation by increasing IL-10 level, in experimental model of Combined Allergic Rhinitis and Asthma Syndrome (CARAS).

Vol. 1, 2019. - 116612
Pôster
Favorite this paper
How to cite this paper?
Abstract

Combined Allergic Rhinitis and Asthma Syndrome (CARAS) is an airway disease that encompasses the clinical manifestations of allergic rhinitis and asthma with the same physiopathology. 4-carvomenthenol (Carvo) is a monoterpene of essential oils that exhibits anti-inflammatory activity. The goal of this study was to test the terpene on CARAS experimental model. BALB/c mice were submitted to the CARAS protocol and treated with 4-carvomentenol (100 - 50 mg/kg). The oral treatment with Carvo significantly reduced inflammatory cell migration mainly eosinophils to the nasal and pulmonary cavities and tissues, decreased the tissue remodeling, clinical signs of rhinitis as well as IgE-allergen specific and IL-13 production. Surprisingly the Carvo treatment increased the regulatory cytokine IL-10 level in the bronchoalveolar lavage. These preliminary data pointed out that the terpene presents anti-inflammatory property by up-regulating the regulatory immune response dependent on IL-10 in CARAS experimental model.

Institutions
  • 1 Centro de Ciências da Saúde / Universidade Federal da Paraíba
  • 2 ASPER/PB / ASPER/PB / Paraíba Association of Renewed Education (ASPER)
  • 3 Universidade Federal da Paraíba
  • 4 Universidade Federal de Minas Gerais
Track
  • Parasitology, Microbiology and Immunology
Keywords
4-carvomenthenol
interleukin-10
CARAS